Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates

分组1 - Coherus BioSciences reported a quarterly loss of $0.35 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.31, and compared to a loss of $0.32 per share a year ago, indicating an earnings surprise of -12.90% [1] - The company posted revenues of $7.6 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 85.46%, and this is a significant decline from year-ago revenues of $77.06 million [2] - Coherus BioSciences shares have declined approximately 29.8% since the beginning of the year, contrasting with the S&P 500's decline of -3.8% [3] 分组2 - The earnings outlook for Coherus BioSciences is currently unfavorable, leading to a Zacks Rank of 4 (Sell), indicating expected underperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.23 on revenues of $16.45 million, and for the current fiscal year, it is -$1.11 on revenues of $100.74 million [7] - The Medical - Biomedical and Genetics industry, to which Coherus BioSciences belongs, is currently in the top 34% of Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]